×
About 640 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  217 results

Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090539
Journal of Clinical Immunology; Lindahl H, Klingström J et. al.

May 11th, 2022 - Immunodeficient individuals often rely on donor-derived immunoglobulin (Ig) replacement therapy (IGRT) to prevent infections. The passive immunity obtained by IGRT is limited and reflects the state of immunity in the plasma donor population at the...

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996444
The Journal of Allergy and Clinical Immunology; van Leeuwen LPM, GeurtsvanKessel CH et. al.

Apr 15th, 2022 - Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity ...

Improved HUMARA for the Detection of X-Linked Agammaglobulinemia Carriers.
https://doi.org/10.1089/gtmb.2021.0139
Genetic Testing and Molecular Biomarkers; Carrillo-Tapia E, Espinosa-Padilla SE et. al.

Apr 9th, 2022 - Background: Fragment analysis of exon 1 of the human androgen receptor, known as HUMARA, is a polymerase chain reaction (PCR)-based method for detecting X-linked agammaglobulinemia (XLA) carriers. This method takes advantage of X-chromosome inacti...

Clinical and genetic findings in two siblings with X-Linked agammaglobulinemia and bron...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981605
BMC Pediatrics; Francisco Junior RDS, de Morais GL et. al.

Apr 7th, 2022 - X-linked agammaglobulinemia (XLA) is an Inborn Errors of Immunity (IEI) characterized by pan-hypogammaglobulinemia and low numbers of B lymphocytes due to mutations in BTK gene. Usually, XLA patients are not susceptible to respiratory tract infect...

SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976534
Journal of Clinical Immunology; Gupta S, Agrawal S et. al.

Apr 4th, 2022 - CD8 cytotoxic T cells (CTLs) play a critical role in the clearance of virally infected cells. SARS-CoV-2-specific CD8 T cells and functional CTLs in natural infections and following COVID-19 vaccine in primary antibody deficiency (PAD) have not be...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  1 results

Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02234791

Sep 9th, 2014 - X-linked agammaglobulinemia (XLA) is a humoral primary immunodeficiency in which affected patients have very low levels of peripheral B cells and a profound deficiency of all immunoglobulin isotypes. Mutations in the gene encoding for Bruton's tyr...

see more →

News  14 results

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL
https://www.onclive.com/view/byrd-discusses-optimizing-ibrutinib-and-idelalisib-in-cll

Dec 20th, 2020 - John C. Byrd, MD In a presentation at the inaugural ASH Meeting on Hematologic Malignancies, John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic ...

Ibrutinib Represents "Transformative" Approach in CLL Treatment
https://www.onclive.com/view/ibrutinib-represents-transformative-approach-in-cll-treatment

Dec 5th, 2020 - Jennifer R. Brown, MD, PhD Jennifer R. Brown, MD, PhD, and John Byrd, MD, leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies, discussed key ques...

BTK Inhibitor Success Puts Focus on Resistance Mechanisms
https://www.onclive.com/view/btk-inhibitor-success-puts-focus-on-resistance-mechanisms

Dec 5th, 2020 - Krithika Subramanian, PhD Less than 5 years after Bruton tyrosine kinase (BTK) inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged. The robust poten...

COVID-19 Outcomes Vary Widely in Patients With Primary Immunodeficiencies
https://www.staging.medscape.com/viewarticle/939374

Oct 20th, 2020 - NEW YORK (Reuters Health) - Clinical outcomes of COVID-19 in patients with primary immunodeficiency diseases range from mild illness to death, according to a small case series. "We were first surprised that we had only a few cases considering how ...

Dyspnea and Night Sweats in a 46-Year-Old Man
https://reference.medscape.com/viewarticle/732961_3

Jan 15th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

see more →

Patient Education  1 results see all →